Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter, randomized, phase 2/3 study
Pau Montesinos(Instituto de Salud Carlos III), Gail J. Roboz(NewYork–Presbyterian Hospital), Claude‐Eric Bulabois(Centre Hospitalier Universitaire de Grenoble), Marion Subklewe(Ludwig-Maximilians-Universität München), Uwe Platzbecker(University Hospital Leipzig), Yishai Ofran(Rambam Health Care Campus), Cristina Papayannidis(University of Bologna), Agnieszka Wierzbowska(Medical University of Lodz), Ho Jin Shin(Pusan National University Hospital), Vadim Doronin(City Clinical Hospital), Stefan Deneberg(Karolinska University Hospital), Su‐Peng Yeh(China Medical University), Mehmet Ali Özcan(Dokuz Eylül University), Steven Knapper(Cardiff University), Jörge E. Cortes(The University of Texas MD Anderson Cancer Center), Daniel A. Pollyea(University of Colorado Anschutz Medical Campus), Gert J. Ossenkoppele(Amsterdam University Medical Centers), Sergio Giralt(Memorial Sloan Kettering Cancer Center), Hartmut Döhner(University Hospital Ulm), Michael Heuser(Medizinische Hochschule Hannover), Liang Xiu(Janssen (United States)), Indrajeet Singh(Janssen (United States)), Fei Huang(Janssen (United States)), Julie S. Larsen(Janssen (United States)), Andrew H. Wei(The Alfred Hospital)
Cited by 100Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis